United States — United States Securities and Exchange Commission & Paragon Therapeutics
2 shared events · Importance 3 · Last updated Aug 20, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — United States Securities and Exchange Commission: Regulator that may investigate; whistleblower program mentioned.
Paragon Therapeutics: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.
Jul 27, 2026 · 293 articles
Business
United States — United States Securities and Exchange Commission: The United States — United States Securities and Exchange Commission declared effective Altor BioScience' shelf registration statement on Form S-3, allowing the public offering to proceed.
Paragon Therapeutics: Altor BioScience was launched based on assets licensed from Paragon Therapeutics, indicating its foundational role in Altor BioScience' existence.
Jun 03, 2026 · 12 articles
50
United States — United States Securities and Exchange Commission investigated securities violations Paragon TherapeuticsCapricor Deramiocel FDA...
50
United States — United States Securities and Exchange Commission investigated securities violations Paragon TherapeuticsCapricor Deramiocel FDA...
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — United States Securities and Exchange Commission and Paragon Therapeutics interact across events, view sentiment trends, and discover connected entities.
Open Dashboard